Symbols / DCTH
DCTH Chart
About
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 351.37M |
| Enterprise Value | 263.42M | Income | 1.20M | Sales | 79.60M |
| Book/sh | 3.25 | Cash/sh | 2.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 96 | IPO | — |
| P/E | 331.67 | Forward P/E | 101.53 | PEG | — |
| P/S | 4.41 | P/B | 3.06 | P/C | — |
| EV/EBITDA | 43.33 | EV/Sales | 3.31 | Quick Ratio | 12.90 |
| Current Ratio | 15.06 | Debt/Eq | 0.84 | LT Debt/Eq | — |
| EPS (ttm) | 0.03 | EPS next Y | 0.10 | EPS Growth | -66.70% |
| Revenue Growth | 83.60% | Earnings | 2026-02-26 | ROA | 4.71% |
| ROE | 1.94% | ROIC | — | Gross Margin | 86.29% |
| Oper. Margin | -1.89% | Profit Margin | 1.50% | Shs Outstand | 34.70M |
| Shs Float | 30.92M | Short Float | 12.34% | Short Ratio | 9.04 |
| Short Interest | — | 52W High | 18.23 | 52W Low | 8.12 |
| Beta | 0.36 | Avg Volume | 515.60K | Volume | 229.26K |
| Target Price | $22.33 | Recom | Strong_buy | Prev Close | $9.74 |
| Price | $9.95 | Change | 2.16% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.33
Mean price target
2. Current target
$9.95
Latest analyst target
3. DCF / Fair value
$-2.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.95
Low
$18.00
High
$30.00
Mean
$22.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-11-05 | main | Stephens & Co. | Overweight → Overweight | $18 |
| 2025-11-04 | reit | BTIG | Buy → Buy | $23 |
| 2025-10-21 | main | Canaccord Genuity | Buy → Buy | $21 |
| 2025-10-20 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-06-23 | reit | Stephens & Co. | Overweight → Overweight | $25 |
| 2025-05-23 | main | HC Wainwright & Co. | Buy → Buy | $29 |
| 2025-03-07 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-01-17 | main | Craig-Hallum | Buy → Buy | $21 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-08-06 | reit | Stephens & Co. | Overweight → Overweight | $25 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-06-28 | init | Craig-Hallum | — → Buy | $18 |
| 2024-05-15 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $25 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-09-07 | main | Canaccord Genuity | Buy → Buy | $21 |
| 2023-08-16 | main | Roth MKM | Buy → Buy | $13 |
- Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Delcath Systems (DCTH) and Certara (CERT) - The Globe and Mail ue, 24 Feb 2026 18
- Interventional oncology firm Delcath sets Feb. 26 2025 results call - Stock Titan hu, 12 Feb 2026 08
- Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge - simplywall.st Fri, 21 Nov 2025 08
- Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years - Yahoo Finance Wed, 03 Dec 2025 08
- Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha ue, 13 Jan 2026 08
- Delcath Systems stock falls despite positive clinical trial results - Investing.com Mon, 20 Oct 2025 07
- Craig-Hallum Maintains Delcath Systems(DCTH.US) With Buy Rating - 富途牛牛 Mon, 23 Feb 2026 15
- Insider Purchase: CHIEF EXECUTIVE OFFICER of $DCTH Buys 11,500 Shares - Quiver Quantitative hu, 13 Nov 2025 08
- Delcath Systems (DCTH) Stock Drops 10% After Lowered Revenue Gui - GuruFocus Mon, 20 Oct 2025 07
- Clear Street Raises Delcath Systems, Inc. (DCTH) Target to $29, Maintains Buy Rating - Finviz Wed, 11 Feb 2026 08
- Q3 Revenue $20.5M — Delcath Systems Reports Positive adjusted EBITDA and $88.9M Cash, Strong 2025 Guidance - Stock Titan Sat, 18 Oct 2025 07
- Delcath: Temporary Headwinds Are No Cause For Concern (NASDAQ:DCTH) - Seeking Alpha hu, 06 Nov 2025 08
- Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st Sat, 09 Aug 2025 07
- Does The Market Have A Low Tolerance For Delcath Systems, Inc.'s (NASDAQ:DCTH) Mixed Fundamentals? - Yahoo Finance Sun, 15 Feb 2026 08
- Delcath: Large Upside With Limited Downside Risk (NASDAQ:DCTH) - Seeking Alpha Mon, 20 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4386 | 38992 | — | Purchase at price 8.89 per share. | SYLVESTER JOHN RICHARD | Director | — | 2025-11-21 00:00:00 | D |
| 1 | 11500 | 98049 | — | Purchase at price 8.53 per share. | MICHEL GERARD J | Chief Executive Officer | — | 2025-11-11 00:00:00 | D |
| 2 | 42000 | 200760 | — | Conversion of Exercise of derivative security at price 4.78 per share. | VUKOVIC VOJISLAV | Officer | — | 2025-06-12 00:00:00 | D |
| 3 | 400000 | 4000000 | — | Conversion of Exercise of derivative security at price 10.00 per share. | ROSALIND ADVISORS, INC. | Unknown | — | 2025-05-05 00:00:00 | I |
| 4 | 400000 | 4000000 | — | Conversion of Exercise of derivative security at price 10.00 per share. | SALAMON STEVEN A. J. | Director | — | 2025-05-05 00:00:00 | I |
| 5 | 400000 | 4000000 | — | Conversion of Exercise of derivative security at price 10.00 per share. | AHARON GILAD S. | Director | — | 2025-05-05 00:00:00 | I |
| 6 | 250000 | 2500000 | — | Conversion of Exercise of derivative security at price 10.00 per share. | ROSALIND ADVISORS, INC. | Director | — | 2024-12-24 00:00:00 | I |
| 7 | 250000 | 2500000 | — | Conversion of Exercise of derivative security at price 10.00 per share. | SALAMON STEVEN A. J. | Director | — | 2024-12-24 00:00:00 | I |
| 8 | 250000 | 2500000 | — | Conversion of Exercise of derivative security at price 10.00 per share. | AHARON GILAD S. | Director | — | 2024-12-24 00:00:00 | I |
| 9 | 16666 | 99996 | — | Conversion of Exercise of derivative security at price 6.00 per share. | MICHEL GERARD J | Chief Executive Officer | — | 2024-10-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 1.89M | -29.79M | -33.69M | -24.32M |
| TotalUnusualItems | -14.07M | -8.00M | ||
| TotalUnusualItemsExcludingGoodwill | -14.07M | -8.00M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -26.39M | -47.68M | -36.51M | -25.65M |
| ReconciledDepreciation | 229.00K | 399.00K | 132.00K | 146.00K |
| ReconciledCostOfRevenue | 6.19M | 635.00K | 686.00K | 671.00K |
| EBITDA | -12.18M | -37.78M | -33.69M | -24.32M |
| EBIT | -12.41M | -38.18M | -33.82M | -24.46M |
| NetInterestIncome | 125.00K | -1.44M | -2.69M | -1.19M |
| InterestExpense | 1.44M | 2.69M | 1.19M | |
| NormalizedIncome | -12.31M | -39.68M | -36.51M | -25.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -26.39M | -47.68M | -36.51M | -25.65M |
| TotalExpenses | 49.62M | 40.25M | 36.57M | 28.09M |
| TotalOperatingIncomeAsReported | -12.41M | -38.18M | -33.85M | -24.53M |
| DilutedAverageShares | 28.51M | 16.23M | 16.23M | 7.15M |
| BasicAverageShares | 28.51M | 16.23M | 16.23M | 7.15M |
| DilutedEPS | -0.93 | -2.94 | -4.12 | -3.59 |
| BasicEPS | -0.93 | -2.94 | -4.12 | -3.59 |
| DilutedNIAvailtoComStockholders | -26.39M | -47.68M | -36.51M | -25.65M |
| NetIncomeCommonStockholders | -26.39M | -47.68M | -36.51M | -25.65M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -26.39M | -47.68M | -36.51M | -25.65M |
| NetIncomeIncludingNoncontrollingInterests | -26.39M | -47.68M | -36.51M | -25.65M |
| NetIncomeContinuousOperations | -26.39M | -47.68M | -36.51M | -25.65M |
| PretaxIncome | -26.39M | -47.68M | -36.51M | -25.65M |
| OtherIncomeExpense | -14.10M | -8.06M | 30.00K | 68.00K |
| OtherNonOperatingIncomeExpenses | -30.00K | -59.00K | 30.00K | 68.00K |
| GainOnSaleOfSecurity | -14.07M | -8.00M | ||
| NetNonOperatingInterestIncomeExpense | 125.00K | -1.44M | -2.69M | -1.19M |
| TotalOtherFinanceCost | -125.00K | 1.44M | ||
| InterestExpenseNonOperating | 1.44M | 2.69M | 1.19M | |
| OperatingIncome | -12.41M | -38.18M | -33.85M | -24.53M |
| OperatingExpense | 43.43M | 39.61M | 35.89M | 27.41M |
| ResearchAndDevelopment | 13.87M | 17.50M | 18.58M | 13.78M |
| SellingGeneralAndAdministration | 29.55M | 22.11M | 17.30M | 13.64M |
| GrossProfit | 31.02M | 1.43M | 2.03M | 2.88M |
| CostOfRevenue | 6.19M | 635.00K | 686.00K | 671.00K |
| TotalRevenue | 37.20M | 2.06M | 2.72M | 3.56M |
| OperatingRevenue | 37.20M | 2.06M | 2.55M | 1.30M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 33.06M | 22.76M | 10.05M | 7.91M |
| ShareIssued | 33.06M | 22.76M | 10.05M | 7.91M |
| NetDebt | 8.02M | |||
| TotalDebt | 1.04M | 10.19M | 15.87M | 16.05M |
| TangibleBookValue | 68.75M | 15.78M | -5.86M | 11.95M |
| InvestedCapital | 68.75M | 25.93M | 9.83M | 27.58M |
| WorkingCapital | 67.62M | 20.71M | 1.42M | 25.20M |
| NetTangibleAssets | 68.75M | 15.78M | -5.86M | 11.95M |
| CapitalLeaseObligations | 1.04M | 37.00K | 186.00K | 416.00K |
| CommonStockEquity | 68.75M | 15.78M | -5.86M | 11.95M |
| TotalCapitalization | 68.75M | 15.78M | 1.98M | 26.96M |
| TotalEquityGrossMinorityInterest | 68.75M | 15.78M | -5.86M | 11.95M |
| StockholdersEquity | 68.75M | 15.78M | -5.86M | 11.95M |
| GainsLossesNotAffectingRetainedEarnings | 82.00K | 135.00K | -83.00K | 18.00K |
| OtherEquityAdjustments | 82.00K | 135.00K | -83.00K | 18.00K |
| RetainedEarnings | -531.55M | -505.16M | -457.48M | -420.98M |
| AdditionalPaidInCapital | 599.88M | 520.58M | 451.61M | 432.83M |
| CapitalStock | 331.00K | 228.00K | 100.00K | 79.00K |
| CommonStock | 331.00K | 228.00K | 100.00K | 79.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.84M | 22.84M | 23.72M | 21.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.70M | 6.39M | 8.99M | 15.22M |
| OtherNonCurrentLiabilities | 766.00K | 840.00K | 1.14M | 207.00K |
| DerivativeProductLiabilities | 0.00 | 5.55M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 933.00K | 0.00 | 7.84M | 15.01M |
| LongTermCapitalLeaseObligation | 933.00K | 0.00 | 207.00K | |
| LongTermDebt | 7.84M | 15.01M | ||
| CurrentLiabilities | 6.14M | 16.45M | 14.73M | 5.95M |
| CurrentDeferredLiabilities | 1.47M | 1.69M | ||
| CurrentDeferredRevenue | 0.00 | 170.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 105.00K | 10.19M | 8.03M | 1.04M |
| CurrentCapitalLeaseObligation | 105.00K | 37.00K | 186.00K | 416.00K |
| CurrentDebt | 10.15M | 7.85M | 621.00K | |
| OtherCurrentBorrowings | 10.15M | 7.85M | 621.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.71M | 1.93M | 1.04M | 893.00K |
| PayablesAndAccruedExpenses | 2.33M | 4.33M | 5.66M | 2.34M |
| CurrentAccruedExpenses | 1.37M | 3.31M | 3.65M | 1.70M |
| InterestPayable | 0.00 | 713.00K | 553.00K | 393.00K |
| Payables | 961.00K | 1.01M | 2.02M | 638.00K |
| AccountsPayable | 961.00K | 1.01M | 2.02M | 638.00K |
| TotalAssets | 76.59M | 38.61M | 17.86M | 33.12M |
| TotalNonCurrentAssets | 2.83M | 1.46M | 1.71M | 1.97M |
| NetPPE | 2.83M | 1.46M | 1.71M | 1.97M |
| AccumulatedDepreciation | -4.95M | -5.08M | -4.93M | -4.83M |
| GrossPPE | 7.78M | 6.53M | 6.64M | 6.80M |
| Leases | 1.58M | 1.79M | 1.77M | 1.80M |
| ConstructionInProgress | 127.00K | 0.00 | ||
| OtherProperties | 2.71M | 1.37M | 1.51M | 1.72M |
| MachineryFurnitureEquipment | 2.04M | 2.06M | 2.06M | 2.06M |
| BuildingsAndImprovements | 1.32M | 1.32M | 1.30M | 1.22M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 73.76M | 37.16M | 16.16M | 31.15M |
| OtherCurrentAssets | 1.39M | 337.00K | 95.00K | 208.00K |
| RestrictedCash | 0.00 | 50.00K | 4.15M | 4.15M |
| PrepaidAssets | 1.15M | 512.00K | 1.87M | 2.54M |
| Inventory | 6.93M | 3.32M | 2.00M | 1.41M |
| FinishedGoods | 824.00K | 126.00K | 133.00K | 0.00 |
| WorkInProcess | 2.26M | 1.75M | 1.10M | 645.00K |
| RawMaterials | 3.85M | 1.44M | 763.00K | 767.00K |
| Receivables | 11.06M | 483.00K | 366.00K | 44.00K |
| TaxesReceivable | 45.00K | 91.00K | ||
| AccruedInterestReceivable | 125.00K | 151.00K | 0.00 | |
| AccountsReceivable | 10.89M | 241.00K | 366.00K | 44.00K |
| CashCashEquivalentsAndShortTermInvestments | 53.23M | 32.45M | 7.67M | 22.80M |
| OtherShortTermInvestments | 20.82M | 19.81M | 0.00 | |
| CashAndCashEquivalents | 32.41M | 12.65M | 7.67M | 22.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.24M | -31.31M | -25.16M | -22.75M |
| RepaymentOfDebt | -10.61M | -6.31M | -714.00K | 0.00 |
| IssuanceOfDebt | 0.00 | 14.44M | ||
| IssuanceOfCapitalStock | 7.02M | 23.08M | 10.86M | 3.92M |
| CapitalExpenditure | -559.00K | -58.00K | -209.00K | -143.00K |
| InterestPaidSupplementalData | 1.24M | 1.46M | 1.87M | 681.00K |
| EndCashPosition | 32.41M | 12.70M | 11.82M | 26.95M |
| BeginningCashPosition | 12.70M | 11.82M | 26.95M | 28.76M |
| EffectOfExchangeRateChanges | -32.00K | 56.00K | -115.00K | 122.00K |
| ChangesInCash | 19.75M | 818.00K | -15.02M | -1.93M |
| FinancingCashFlow | 39.41M | 51.78M | 10.14M | 20.82M |
| CashFlowFromContinuingFinancingActivities | 39.41M | 51.78M | 10.14M | 20.82M |
| NetOtherFinancingCharges | 18.36M | |||
| ProceedsFromStockOptionExercised | 43.00M | 35.01M | 0.00 | 2.46M |
| NetCommonStockIssuance | 7.02M | 23.08M | 10.86M | 3.92M |
| CommonStockIssuance | 7.02M | 23.08M | 10.86M | 3.92M |
| NetIssuancePaymentsOfDebt | -10.61M | -6.31M | -714.00K | 14.44M |
| NetLongTermDebtIssuance | -10.61M | -6.31M | -714.00K | 14.44M |
| LongTermDebtPayments | -10.61M | -6.31M | -714.00K | 0.00 |
| LongTermDebtIssuance | 0.00 | 14.44M | ||
| InvestingCashFlow | -981.00K | -19.71M | -209.00K | -143.00K |
| CashFlowFromContinuingInvestingActivities | -981.00K | -19.71M | -209.00K | -143.00K |
| NetInvestmentPurchaseAndSale | -422.00K | -19.65M | 0.00 | |
| SaleOfInvestment | 52.03M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -52.45M | -19.65M | 0.00 | |
| NetPPEPurchaseAndSale | -559.00K | -58.00K | -209.00K | -143.00K |
| PurchaseOfPPE | -559.00K | -58.00K | -209.00K | -143.00K |
| OperatingCashFlow | -18.68M | -31.25M | -24.95M | -22.60M |
| CashFlowFromContinuingOperatingActivities | -18.68M | -31.25M | -24.95M | -22.60M |
| InterestPaidCFO | -847.00K | 0.00 | ||
| ChangeInWorkingCapital | -15.52M | -906.00K | 2.11M | -5.76M |
| ChangeInOtherWorkingCapital | -170.00K | -2.43M | ||
| ChangeInOtherCurrentLiabilities | -101.00K | -537.00K | 621.00K | -322.00K |
| ChangeInPayablesAndAccruedExpense | 479.00K | -199.00K | 1.80M | -3.28M |
| ChangeInAccruedExpense | -2.15M | |||
| ChangeInPayable | 479.00K | -199.00K | -1.14M | |
| ChangeInAccountPayable | 479.00K | -199.00K | -1.14M | |
| ChangeInPrepaidAssets | -1.64M | 1.03M | 774.00K | 813.00K |
| ChangeInInventory | -3.61M | -1.32M | -587.00K | -557.00K |
| ChangeInReceivables | -10.65M | 125.00K | -322.00K | 13.00K |
| ChangesInAccountReceivables | -10.65M | 125.00K | -322.00K | 13.00K |
| OtherNonCashItems | 593.00K | 936.00K | 1.37M | 831.00K |
| StockBasedCompensation | 9.77M | 8.15M | 7.94M | 7.83M |
| AmortizationOfSecurities | -587.00K | -151.00K | 0.00 | |
| DepreciationAmortizationDepletion | 229.00K | 399.00K | 132.00K | 146.00K |
| DepreciationAndAmortization | 229.00K | 399.00K | 132.00K | 146.00K |
| Depreciation | 229.00K | 399.00K | 132.00K | 146.00K |
| OperatingGainsLosses | 14.07M | 8.00M | ||
| GainLossOnInvestmentSecurities | 14.07M | 8.00M | ||
| NetIncomeFromContinuingOperations | -26.39M | -47.68M | -36.51M | -25.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DCTH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|